The spotlight turns to DexCom after Thursday’s market close as the continuous glucose monitoring specialist releases its final 2025 results. While preliminary January figures have largely set expectations for revenue, the investment community is keenly focused on the company’s 2026 guidance and the profitability metrics of its flagship G7 system.
- Earnings Date: Thursday, February 12, 2026 (after market close)
- Expected Q4 Revenue: Approximately $1.26 billion (+13%)
- 2026 Revenue Forecast: $5.16 to $5.25 billion
- Target Operating Margin (Non-GAAP): 22% to 23%
Profitability and Guidance Under Scrutiny
Beyond the top-line numbers, which are anticipated to show annual 2025 revenue near $4.66 billion, the core of the report will be DexCom’s forward-looking statements. The market seeks confirmation of an 11% to 13% organic growth target for the coming year, which would translate to revenue approaching $5.25 billion. The key question is whether this momentum can be sustained in an increasingly competitive landscape.
Profitability indicators will receive equal attention. Analysts are monitoring the projected Non-GAAP gross margin, expected between 63% and 64%, for signs of efficient manufacturing cost control for the G7 product. Furthermore, the stated goal of a 22% to 23% operating margin for 2026 is viewed as a critical benchmark for the company’s financial health and operational efficiency.
Should investors sell immediately? Or is it worth buying DexCom?
Insider Activity Sends a Mixed Signal
Recent ownership data presents a contrasting picture. Institutional investor Principal Financial Group reduced its stake by nearly 29% in the third quarter of 2025. However, a notable vote of confidence came from within: new Chief Executive Officer Jacob Steven Leach recently purchased 18,200 shares at $55.04 each. Such insider buying, particularly from a CEO who just assumed the role at the start of the year, is often interpreted as a strong signal of internal confidence in the firm’s long-term trajectory.
The broader MedTech sector is currently marked by caution, as evidenced by recent target price revisions for peers like Edwards Lifesciences. For DexCom, tomorrow’s report will demonstrate if the growth narrative surrounding its G7 system continues to meet Wall Street’s expectations. Alongside the hard financial data, management commentary on competitive dynamics and regulatory progress will likely be a significant driver for the stock’s near-term direction.
Ad
DexCom Stock: Buy or Sell?! New DexCom Analysis from February 11 delivers the answer:
The latest DexCom figures speak for themselves: Urgent action needed for DexCom investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 11.
DexCom: Buy or sell? Read more here...
